
Please try another search
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company’s lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Name | Age | Since | Title |
---|---|---|---|
Paula Soteropoulos | 56 | 2023 | Independent Director |
Alison F. Lawton | 63 | 2020 | Independent Chairman of the Board |
Marino Garcia | 58 | 2021 | President, CEO & Director |
Jonathan Violin | 50 | 2019 | Independent Director |
Anne M. McGeorge | 64 | 2019 | Independent Director |
Simon Read | - | 2025 | Director |
Steven J. Romano | 66 | 2024 | Independent Director |
Sujay R. Kango | 61 | 2025 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review